Daily Updates on Generic Entry, Litigation, Biosimilars, and more …
Want insights into the biggest revenue-changing events?
Billions of dollars in sales can evaporate overnight as drug patents expire and competitors enter the market.
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects
Completed
Lantheus Medical Imaging
Phase 1/Phase 2
2005-01-01
The purpose of this Phase I-II multicenter clinical trial is to establish dosimetry and
safety profiles for CARDIOLITE® (Technetium Tc99m Sestamibi) in pediatric subjects.
A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging
Terminated
Forest Laboratories
Phase 2
2005-07-01
The primary purpose of this study is to determine the optimal time for myocardial perfusion
imaging with Technetium Tc99m Sestamibi following the administration of BMS068645. The
safety of BMS068645 will also be studied.
Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
Withdrawn
National Cancer Institute (NCI)
Phase 1
2007-05-01
RATIONALE: Ammonium tetrathiomolybdate may stop the growth of non-small cell lung cancer by
blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor
cells. Giving ammonium tetrathiomolybdate together with radiation therapy may kill more
tumor cells.
PURPOSE: This phase I trial is studying the side effects of giving radiation therapy
together with ammonium tetrathiomolybdate in treating patients with stage I, stage II, or
stage III non-small cell lung cancer.
Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
Withdrawn
Roswell Park Cancer Institute
Phase 1
2007-05-01
RATIONALE: Ammonium tetrathiomolybdate may stop the growth of non-small cell lung cancer by
blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor
cells. Giving ammonium tetrathiomolybdate together with radiation therapy may kill more
tumor cells.
PURPOSE: This phase I trial is studying the side effects of giving radiation therapy
together with ammonium tetrathiomolybdate in treating patients with stage I, stage II, or
stage III non-small cell lung cancer.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
